BeyondSpring CEO On Plinabulin's Dual Regulatory Pathway For US and China
BeyondSpring’s lead clinical asset, plinabulin, is currently in late-stage global registrational studies for the prevention of chemotherapy-induced neutropenia and treatment of lung cancer, with read-outs expected soon. CEO Lan Huang discussed coming catalysts and their potential with Scrip.
You may also be interested in...
Lessons learned about blinding and stratification from Pfizer and Merck KGaA’s earlier Phase III disappointment shaped the design of BeyondSpring's ongoing Phase III trial of plinabulin in second- and third-line non-small cell lung cancer.
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
The Nordic region’s vibrant life sciences ecosystem will be the chief focus for newly created Eir Ventures, a strategic partnership and investment company.